Live Breaking News & Updates on Rachel Mcminn

Stay updated with breaking news from Rachel mcminn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Rachel Mcminn , Human Research Ethics Committee , Neurogene Inc , American Society Of Gene , Drug Administration , Exchange Commission , Research Development Rd Expenses , Australian Therapeutic Goods Administration , Chief Executive Officer , Recent Highlights , American Society , Cell Therapy , Annual Meeting , Annual Goldman Sachs Global Healthcare Conference , International Rett Syndrome Foundation , Rett Syndrome Scientific Meeting , Neoleukin Therapeutics , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Tables Follow , Consolidated Statements , Reverse Merger , Pre Closing Financing , Net Loss Per Share Attributable ,

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

NGN-401 has been generally well-tolerated by first three patients dosed, with three to nine months of follow-up

No signs or symptoms of overexpression toxicity, including in one patient with a mild. ....

United States , Bernhard Suter , Rachel Mcminn , American Society Of Gene , Company Annual Report On Form , Exchange Commission , Neurogene Inc , American Society , Cell Therapy , Chief Executive Officer , Rett Syndrome , Clinical Global Impression Severity , Medical Director , Blue Bird Circle Rett Center , Texas Children , Associate Professor , Baylor College , Private Securities Litigation Reform Act , Annual Report ,

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

NGN-401 has been generally well-tolerated by three patients with multiple months of follow-up

. ....

United States , United Kingdom , Rachel Mcminn , Neurogene Inc , Company Annual Report On Form , American Society For Gene , Exchange Commission , American Society , Cell Therapy , Chief Executive Officer , Poster Presentation , Preliminary Safety Results , Novel Regulated Gene Therapy , Rett Syndrome , Exhibit Hall , Private Securities Litigation Reform Act , Annual Report ,

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

22.04.2024 - Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing . Seite 1 ....

United States , Rachel Mcminn , American Society For Gene , Neurogene Inc , American Society , Cell Therapy , Chief Executive Officer ,

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Julie. ....

United States , Rachel Mcminn , Head Of Clinical Development , Securities Exchange , Neurogene Inc , Teva Pharmaceutical Industries , Neoleukin Therapeutics Inc , Department Of Medicine At Massachusetts , Avanir Pharmaceuticals , Company Current Report On Form , Harvard College , Harvard Medical School , Julie Jordan , Chief Medical , Chief Medical Officer , Homology Medicines , Chief Executive Officer , Senior Vice President , Clinical Development , Cerevel Therapeutics , Teva Pharmaceutical , Clinical Instructor , Massachusetts General Hospital , Internal Medicine , Harvard Medical , Securities Exchange Act ,